

KESIMPTA - How does KESIMPTA work

[Prescribing information](#)

Image



Image



 **Kesimpta**[®]▼
ofatumumab

How does **KESIMPTA**[®]▼ (ofatumumab) work?

KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.¹

For full safety information, please refer to the [KESIMPTA Summary of Product Characteristics \(SmPC\)](#).¹

KESIMPTA has been shown to act on B-cells in MS patients, targeting them and inducing cell lysis.¹ KESIMPTA is an anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody that

selectively targets and binds to the CD20 protein.¹ This protein is expressed on the surface of the majority of B-cells, making it a valuable target for precise MS treatment.² KESIMPTA is thought to work by selectively binding to sites on both the small and the large extracellular loops of CD20 protein on B-cells.²⁻⁴

The precise mechanism of action by which KESIMPTA exerts its therapeutic effects is unknown.

To learn about how KESIMPTA targets B-cell subsets that facilitate inflammation, and how it causes CD20-inducing lysis of these B-cells, watch this short video.¹

 **Kesimpta™**
ofatumumab 20 mg
injection

Binding to B Cells

Prescribing information and adverse events reporting for KESIMPTA can be found on the web page where this video is hosted and with a Novartis representative. This video contains promotional content and has been developed by Novartis Pharmaceuticals Ltd. This video is intended for UK healthcare professionals only.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report. If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com.

 **NOVARTIS**

UK | March 2023 | 109625-1

VIDEO

CD, cluster of differentiation; IgG, immunoglobulin G; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

References:

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.
2. Zhang B. *mAbs* 2009;1(4):326–331.
3. Gupta IV & Jewell RC. *Ann N Y Acad Sci* 2012;1263:43–56.
4. Martin R, et al. *Eur J Immunol* 2016;46:2078–2090.

Image

Safety profile

UK | January 2025 | 443403

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/neuroscience/kesimpta/moa/mechanism-vid eo>